Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback